Expression of EGFR and p53 in head and neck tumors among Sudanese patients

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6415-6418

  Abusail, Mustafa Saadalnour ^a   Dirweesh, Ahmed Mohmed Ahmed ^b   Salih, Rashid Awad Abdalla ^b   Gadelkarim, Ahmed Hussain ^b  

^a Faculty of Medical laboratory Sciences   (Sudan)

^b UNIVERSITY OF HAIL   (Saudi Arabia)

Author keywords

EGFR; Head and neck cancer; P53; Sudanese

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; CHILD; ENZYMOLOGY; FEMALE; GENETICS; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SUDAN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SUDAN; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 85047687395     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6415     Document Type: Article

References (39)

1. Andl T, Kahn T, Pfuhl A, et al (1998). Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res, 58, 5-13.
2. Bénard J, Douc-Rasy S, Ahomadegbe JC (2003). TP53 family members and human cancers. Hum Mutat, 21, 182-91.
3. Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEnglJ Med, 354, 567-578.
4. Brachman DG, Graves D, Vokes E, et al (1992). Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res, 52, 4832-3.
5. Calzolari A, Chiarelli I, Bianchi S, et al (1997) Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol, 107, 7-11.
6. Chung CH, Gillison ML (2009) Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res, 15, 6758-62.
7. Chung CH, Ely K, McGavran L (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clinical Oncol, 24, 4170-6.
8. Ciardiello F, Tortora G (2003). Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer, 39, 1348-54.
9. EgloffAM, Grandis J (2006). Epidermal growth factor receptortargeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets. 10, 639-47.
10. Fakhry C, Westra WH, Li S (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J National Cancer Institute, 100, 261-9.
11. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
12. Santarelli A, Lo Russo L, Bambini F, Campisi G, Lo Muzio L (2009). New perspectives in medical approach to therapy of head and neck squamous cell carcinoma. Minerva Stomatol, 58, 445-52.
13. Gallo O, Bianchi S, Giovannucci-Uzzielli ML, et al (1995). p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. Br J Cancer, 71, 1008-12.
14. Gallo O, Bianchi S (1995). p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract. Eur J Cancer B Oral Oncol, 31, 53-7.
15. Gillison ML, Shah KV (2001). Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol, 13, 183-8.
16. Goon PK, Stanley MA, Ebmeyer J, et al (2009). HPV & head and neck cancer: a descriptive update. Head Neck Oncol, 1, 36.
17. Grandis JR, Chakraborty A, Melhem MF(1997). Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene, 15, 409-16.
18. Grandis JR, Chakraborty A, Zeng Q (1998). Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem, 69, 55-62.
19. Grandis JR, Chakraborty A, Zeng Q (1980). Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem, 69, 55-62.
20. Grandis JR, Sok JC (2004). Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther, 102, 37-46.
21. Grandis JR, Tweardy DJ (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res, 53, 3579-84.
22. Grandis JR, Zeng Q, Tweardy DJ (1996). Retinoic acid normalizes the increased gene transcription rate of TGFalpha and EGFR in head and neck cancer cell lines. Nat Med, 2, 237-40.
23. Helton ES, Chen X (2007). p53 modulation of the DNA damage response. J Cell Biochem, 100, 883-96.
24. Hoffmann TK, Schirlau K, Sonkoly E, et al (2009). A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer, 124, 2589-96.
25. Homann N, Nees M, Conradt C, et al (2001). Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res, 7, 290-6.
26. Knowles LM, Stabile LP, EgloffAM, et al (2009). HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res, 15, 3740-50.
27. Kumar B, Cordell KG, Lee JS (2008). EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol, 26, 3128-37.
28. Lassen P (2010). The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol, 3, 371-80.
29. Lee JW, Soung YH, Kim SY (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res, 11, 2879-82.
30. Lukas J, Lukas C, Bartek J (2004). Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair, 3, 997-1007.
31. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 2, 74-108.
32. Pu YS, Huang CY, Kuo YZ, et al (2009). Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. J Biomed Sci, 16, 127-32.
33. Rischin D, Young R, Fisher R (2009). Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. J Clin Oncol, 27, 6004.
34. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG (2010). Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol, 25, 13.
35. Sherr CJ, McCormick F (2002). The RB and p53 pathways in cancer. Cancer Cell, 2, 103-12.
36. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP (2010). Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer, 5, 4.
37. Smith EM, Wang D, Kim Y, et al (2008). P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol, 44, 133-42.
38. Soulieres D, Senzer NN, Vokes EE, et al (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 22, 77-85.
39. Temam S, Kawaguchi H, El-Naggar AK, et al (2007). Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol, 25, 2164-70.